Attend Canada’s most highly anticipated diabetes-related conference in the comfort of your own home and learn about significant advances in diabetes research, treatment, and care. Through the course of the conference, delegates will have the opportunity to attend original research presentations and take part in information sharing with leading diabetes, endocrinology, and related field experts. More information on programming to come! Grab your spot today.
For more information about the 2020 Diabetes Canada/CSEM Professional Conference, please visit dcanconference.ca
*Note: all times in ET. Schedule is tentative and may change as program is confirmed.Theme: Shifting the Paradigm in Patient-Oriented Research: Are We There Yet?
AgendaDr. Vallis is a registered health psychologist based in Halifax, Canada. He is a Health Behaviour Change Consultant and Associate Professor in Family Medicine at Dalhousie University. His main area of expertise is adult health psychology, with an emphasis on obesity, diabetes, cardiovascular risk and gastroenterology. He spends most of his time training health-care providers in behaviour change for chronic disease management. He regularly supervises clinical and academic students at Dalhousie and is active in research on motivation, behavioural change and adaptation to chronic disease. He consults nationally, as well as internationally, and is heavily involved in academic publications, journal editing, and clinical practice guidelines (2020 and 2006 Canadian Clinical Practice Guidelines for the Management of Obesity and 2018, 2013, 2004 Diabetes Canada Clinical Practice Guidelines). He was recently awarded a Queen’s Diamond Jubilee Medal by the Government of Canada on the recommendation of Diabetes Canada (formerly the Canadian Diabetes Association).
I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Consultant and speaker/trainer: Novo Nordisk; Sanofi, Abbvie, Lifescan, Merck
Dr. Yardley completed her PhD in Population Health at the University of Ottawa in 2011. Her doctoral thesis focused on the effects of resistance exercise, on its own or combined with aerobic exercise, in physically active individuals with type 1 diabetes. She is now an Associate Professor at the University of Alberta, and part of the Physical Activity and Diabetes Laboratory at the Alberta Diabetes Institute. Dr. Yardley is still performing research related to type 1 diabetes and exercise. Her current projects focus on resistance exercise and high intensity intermittent intervals, with a particular interest in sex-related differences in blood glucose responses to these modalities. She is a co-author of the 2016 American Diabetes Association Position Statement on Diabetes and Exercise/Physical Activity and a recipient of the Heart and Stroke Foundation of Canada Alberta New Investigator Award.
I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Speaker's fees: Dexcom Canada
In-kind research support: OneTouch Canada, Abbott Nutrition Canada, Dexcom Canada
Dr. Sigal is Professor of Medicine, Kinesiology, Cardiac Sciences and Community Health Sciences at the Cumming School of Medicine, University of Calgary. He is active in clinical medicine, teaching and research.
Dr. Sigal completed residencies in Internal Medicine and Endocrinology at McGill University, and a research fellowship at the McGill Nutrition and Food Sciences Centre. He then completed a Master of Public Health degree and a research fellowship in Epidemiology and Genetics at Harvard University. He has held a Health Senior Scholar award from Alberta Innovates-Health Solutions, and previously a Canadian Institutes of Health Research (CIHR) New Investigator Award. Dr. Sigal’s research focuses on clinical trials related to physical activity, diabetes, kidney disease and cardiovascular disease.
Dr. Sigal has been the lead author of the guidelines on Physical Activity/Exercise for Diabetes Canada (2003, 2008, 2013, 2018) and the American Diabetes Association (2006), and co-Chair of the writing group for the American Diabetes Association Position Statements on Physical Activity/Exercise and Diabetes in 2010 and 2016. He contributed to the chapters on Chronic Diseases and Cardiometabolic Health for the 2018 Physical Activity Guidelines for Americans
I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Honoraria for advisory board meeting: Novo Nordisk
Local PI for multicentre trials: Novo Nordisk, Sanofi
Bio---TBA
I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Speaker: ABBOTT, AZ, MERCK, JANSSEN, BI/LILY, SANOFI, BAUSCH, NOVO NORDISK
Grants: NovoNordisk, Astra Fenica
Bio--- TBA
SPEAKERS BUREAU/HONORARIA: AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medtronic, Merck, NovoNordisk, Sanofi, Takeda
CONSULTING FEES: AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medtronic, Merck, Mylan, NovoNordisk, Sanofi
Bio--- TBA
SPEAKERS BUREAU/HONORARIA: AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medtronic, Merck, NovoNordisk, Sanofi, Takeda
CONSULTING FEES: AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medtronic, Merck, Mylan, NovoNordisk, Sanofi
Kate has been heavily involved in the Do-It-Yourself #wearenotwaiting movement since her daughter Sydney was diagnosed with type 1 diabetes at the age of 8. With a background in information technology and graphic design, Kate has lent her skillset to developing diabetes watch faces for remote monitoring used by patients worldwide. Kate has created an online patient-driven support community for people who are exploring DIY closed-loop solutions and continues to advocate for all people with diabetes to have access to the best tools to manage their diabetes.
I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Feig is a Professor of Medicine in the Division of Endocrinology and Metabolism at the University of Toronto, and holds a cross-appointment in both the Department of Obstetrics and Gynecology and the Department of Health Policy, Management and Evaluation. She is a Senior Clinician Scientist at the Lunenfeld-Tanenbaum Research Institute, and an Adjunct Scientist at the Institute for Clinical and Evaluative Sciences. She is Head of the Diabetes and Endocrine in Pregnancy Program at Mount Sinai Hospital, Chair of the University of Toronto Diabetes in Pregnancy Study Group and Past Chair of the Diabetes in Pregnancy Interest Group for the American Diabetes Association. Her research focus is in the area of diabetes in pregnancy and she was awarded the Canadian Diabetes in Pregnancy Study Group Award for Excellence.
I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Bajaj is an Endocrinologist and Director of late-phase research at LMC Healthcare. Dr Bajaj started his Endocrinology practice with LMC Brampton in 2009, after completing his clinical fellowship at the Cleveland Clinic (Ohio, USA). Dr Bajaj’s medical education was at Maulana Azad Medical College (New Delhi, India), following which he attained a Masters of Public Health (Epidemiology) at State University of New York in Albany (New York, USA).
Dr. Bajaj is a Research Associate at Mount Sinai Hospital, Toronto, and an adjunct lecturer at McMaster University. He is the principal investigator for the Canadian Diabetes Prevention Program (CDPP), a virtual one-year health and wellness coaching program funded by the Public Health Agency of Canada.
He volunteers with numerous community public health organizations, as well as media programs, with the intent of raising public awareness on diabetes prevention and treatment, with a specific focus on the South Asian origin population in Canada. He is the founder of STOP Diabetes Foundation, a registered charitable organization working to reduce the burden of diabetes in Peel region of Ontario. Dr. Bajaj serves Diabetes Canada on the Executive Board of the Professional Section Executive and as the Vice Chair of clinical practice guidelines.
I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Honorariums: Banting & Best Diabetes Centre, Brain and Cognition Discovery Found., Diabetes Canada, Eli Lilly, Hu.
Piad to LMC (Institution): Amgen, AstraZeneca, Boehringer Ingelheim, Ceapro, Eli Lilly, Gilead, Janssen, Kowa, Madrigal, Merck
Dr. Senior is Professor of Medicine at the University of Alberta. His research activities and clinical practice are focused on the management and prevention of type 1 diabetes and its complications, and beta cell replacement therapies, including islet transplantation.
He serves as the Chair of the Clinical Practice Guidelines Steering Committee and is a member of the Diabetes Canada Board of Directors.
I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Honorarium for CGP chair role: Diabetes Canada
Grant funding to my institution for participation as local PI in clinical trials: Novo Nordisk, Viacyte, JDRF
Dr. Lipscombe is the Director of the Division of Endocrinology at Women’s College Hospital and an Associate Professor of Medicine at University of Toronto. She completed her MD from McGill University in 1998, followed by Internal Medicine and Endocrinology training and an MSc in Clinical Epidemiology from University of Toronto. Dr. Lipscombe is a Clinician Scientist with a research focus on the epidemiology, care and prevention of diabetes, and she holds a Diabetes Investigator Award from Diabetes Canada.
I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Long studied Medicine and did her residence training in Internal Medicine and Endocrinology at the University of Montreal. She works at the CISSS Laval and at the Laval Regional Diabetes Center as a Clinical Endocrinologist and Medical Coordinator. She was also an associated member at the Montreal University Hospital Center from 2006 to 2011. Her particular interests are teaching (patients, trainees and family doctors) and the endocrinology of pregnancy.
I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Makokis is from the Saddle Lake Cree Nation in Northern Alberta. He holds a Bachelor of Science in Nutrition and Food Sciences ('04), a Master of Health Science in Community Nutrition from the University of Toronto ('06) and a Doctorate in Medicine from the University of Ottawa ('10). He received certification from the Aboriginal Family Medicine Training Program at the University of British Columbia ('12). Currently, he works as the sole Family Physician at Kehewin Health Services on Kehewin Cree Nation. Dr. Makokis leads one of North America’s most progressive and successful transgender focused medical practices in south Edmonton, and has been featured on the CBC, AJ+, and the Thompson Reuters Foundation for his work in this area.
His strong connections to his cultural beliefs, nehiyaw maskihkiya, preventative health through the Cree medical system, spirituality, and Two-spirit perspective has helped him save lives within the LGBTQ2 and First Nation communities. Dr. Makokis participated alongside his husband as ""Team Ahkameyimok"" on Season 7 of The Amazing Race Canada and won. Dr. Makokis currently serves on the Board of the Waakebiness-Bryce Institute of Indigenous Health at the University of Toronto and Indigenous Advisory Council at McEwan University, and is the former Board Chair of the inaugural Indigenous Wisdom Council of Alberta Health Services. He has previously served on the boards of the Indigenous Physicians Association of Canada, Indspire and the Two Spirit Circle.
I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Cheng is a member of the Division of Endocrinology and Metabolism at Credit Valley Hospital in Mississauga and St. Michael's Hospital in Toronto and is an Associate Professor in the Department of Medicine at the University of Toronto. She completed medical school, internal medicine and Endocrinology training at the University of Toronto and has completed the Master Teacher Program offered through the Department of Medicine. She has served on the Expert Committee for the 2003 Diabetes Canada clinical practice guidelines, the Steering and Expert Committees for the 2008 revision and served as Chair of the 2013 Diabetes Canada clinical practice guidelines. She is currently the Chair of the Professional Section of Diabetes Canada and an Associate Editor for the Canadian Journal of Diabetes. She is Past-Chair of the Guidelines Committee for the Canadian Society of Endocrinology and Metabolism. She has received a Certificate of Recognition from the Ontario College of Family Physicians, the national Charles H. Best Award and the Gerald S. Wong Service Award from Diabetes Canada in recognition of her contributions.
Speaking honoraria: Brandaide, Liv Agency, Meducomm, EOCI, Antibody Communications, Bridge Communications, Sea Courses, Sutherland Global Services Canada ULC, Abbott, Astra Zeneca, Bausch, Boehringer Ingelheim, Eli Lilly, Janssen, HLS Therapeutics, Medtronic, Merck, Novo Nordisk, Sanofi
Advisory board member: Abbott, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medtronic, Merck, Medtronic, Novartis, Novo Nordisk, Sanofi, HLS Therapeutics
Clinical trial investigator / steering committee member: Eli Lilly, Boehringer Ingelheim, Sanofi, Applied Therapeutics
Dr. Louis Girard joined the Division of Nephrology at the University of Calgary in July of 2010. He is a Nephrologist and Clinical Associate Professor. Within the Division of Nephrology, Dr. Girard focuses on clinical immunology and infectious diseases in chronic kidney disease patients. He is the medical director of the Glomerulonephritis Clinic and the Medical Director of Apheresis. Furthermore, he has developed a multi-disciplinary rare diseases clinic that operates out of the Southern Alberta Renal Program. In addition to patients with GN/Vasculitis, this clinic focuses on patients with complement dysregulation, Tuberous Sclerosis and ADPKD. Dr. Girard has a strong clinical research interest. He is currently the local primary investigator on numerous global trials in glomerulonephritis and vasculitis. Dr. Girard has a strong commitment to education and has won numerous awards for his teaching contributions at all levels of medical training.
Honoraria for CME and educational slide development: Alexion, Bayer, BI-Lilly, Astra Zeneca, Janssen, Merck, Otsuka, Bausch Health Funded grants or clinical trials: Otsuka
Member: CDP Network
Dr. Cheng is a member of the Division of Endocrinology and Metabolism at Credit Valley Hospital in Mississauga and St. Michael's Hospital in Toronto and is an Associate Professor in the Department of Medicine at the University of Toronto. She completed medical school, Internal Medicine and Endocrinology training at the University of Toronto and has completed the Master Teacher Program offered through the Department of Medicine. She has served on the Expert Committee for the 2003 Diabetes Canada clinical practice guidelines, the Steering and Expert Committees for the 2008 revision and served as Chair of the 2013 Diabetes Canada clinical practice guidelines. She is currently the Chair of the Professional Section of Diabetes Canada and an Associate Editor for the Canadian Journal of Diabetes. She is Past-Chair of the Guidelines Committee for the Canadian Society of Endocrinology and Metabolism. She has received a Certificate of Recognition from the Ontario College of Family Physicians, the national Charles H. Best Award and the Gerald S. Wong Service Award from Diabetes Canada in recognition of her contributions.
I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Abbott, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk, Bayer, Sanofi, HLS Terapeutics, Eisa
Dr. Yardley completed her PhD in Population Health at the University of Ottawa in 2011. Her doctoral thesis focused on the effects of resistance exercise, on its own or combined with aerobic exercise, in physically active individuals with type 1 diabetes. She is now an Associate Professor at the University of Alberta, and part of the Physical Activity and Diabetes Laboratory at the Alberta Diabetes Institute. Dr. Yardley is still performing research related to type 1 diabetes and exercise. Her current projects focus on resistance exercise and high intensity intermittent intervals, with a particular interest in sex-related differences in blood glucose responses to these modalities. She is a co-author of the 2016 American Diabetes Association Position Statement on Diabetes and Exercise/Physical Activity and a recipient of the Heart and Stroke Foundation of Canada Alberta New Investigator Award.
I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Speaker's fees: Dexcom Canada
In-kind research support: OneTouch Canada, Abbott Nutrition Canada, Dexcom Canada
Dr. McGavock is an Associate Professor in the Department of Pediatrics and Child Health within the Faculty of Health Sciences at the University of Manitoba. He is currently the co-leader of the DREAM Theme at the Children's Hospital Research Institute of Manitoba. Dr. McGavock held a CIHR New Investigator Salary Award from 2010-2014 and, from 2014-2019, held a CIHR Applied Health Chair in Obesity and Resilience in Indigenous Youth. He is currently one of 12 PIs for the Diabetes Action Canada SPOR Network and the PI for a CIHR Pathways Component 3 team grant focused on prevention of type 2 diabetes among Indigenous youth.
Dr. MacDonald completed his PhD in Toronto and followed this with postdoctoral research in Lund, Sweden, and in Oxford. Since 2006, he has run a laboratory at the University of Alberta in Edmonton that has focused on understanding cells in the pancreas that make insulin and other hormones.
I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Corkey has been the Zoltan Kohn Professor of Medicine and Vice Chair for Research in the Department of Medicine at Boston University. Dr. Corkey has been a leader in the fields of diabetes and obesity research for over 50 years, with about 200 related publications and 40 years of continuous government research support. The Corkey laboratory is engaged in research on obesity and diabetes, with a particular focus on metabolic signal transduction in ß-cells, adipocytes and hepatocytes, intercellular communication via circulating redox and the role of hyperinsulinemia in obesity and diabetes. Projects in metabolic regulation have been ongoing since 1981 using such techniques as single cell imaging, metabolic profiling, ionic fluxes and membrane potential, respiration, redox state, reactive oxygen species generation and diet-induced obesity and diabetes models. She does seminal work on the molecular basis of nutrient signaling that has a major impact on our current understanding of health and disease. Finally, Barbara has received numerous honors, including the NIH MERIT Award, National Honorary Membership in Iota Sigma Pi, the National Honor Society of Women in Chemistry, Women in Science Lecturer at the Boston Museum of Science, the George Bray Founders Award of the Obesity Society, the Charles H. Best Lectureship and Award, University of Toronto, and the Banting Medal for Scientific Achievement from the American Diabetes Association.
I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Wicklow is a pediatric endocrinologist, Associate Professor in Pediatrics and Child Health at the University of Manitoba, and Clinician Scientist at the Children's Hospital Research Institute of Manitoba. Her research focuses on the determinants of childhood onset type 2 diabetes and renal complications. She is a principle investigator on 2 cohort studies; the next generation study, which examines the intergenerational risk of type 2 diabetes, and the iCARE cohort study (co-led by Dr Allison Dart), which is examining the psychological and sociological risks for the development of early renal disease in youth with type 2 diabetes. She works closely in partnership with Indigenous communities, families and patients to conduct relevant, patient-oriented research aimed to reduce health disparity and its impacts on First Nations families as it relates to type 2 diabetes.
I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Bruin has been an Assistant Professor at Carleton University in the Department of Biology and Institute of Biochemistry since September 2016. Her lab studies the pathogenesis of diabetes with a focus on islet biology, pancreas development and toxicology. In particular, she is investigating how exposure to persistent environmental pollutants, either during fetal development or adulthood, influences diabetes incidence. Dr. Bruin’s lab is funded by CIHR, NSERC and the Ontario Institute of Regenerative Medicine.
I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Gilbert completed his medical degree, Internal Medicine training and Endocrinology residency at the University of Toronto. He is an associate professor at the University of Toronto. He is the Program Director for adult endocrinology and metabolism at the University of Toronto. He has authored a chapter in the 2013 and 2018 Diabetes Canada clinical practice guidelines and was a member of the Steering Committee of the 2018 Diabetes Canada guidelines. He is on the Executive and is a National Editor for the Canadian Journal of Diabetes. He is a passionate teacher and his academic interest is in undergraduate, postgraduate and continuing medical education in diabetes and endocrinology. He has received numerous awards for outstanding teaching.
I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Sims is a Physician Scientist specializing in pediatric endocrinology, with a long-term goal of addressing clinically relevant problems in diabetes utilizing molecular discovery. Her research focus revolves around the investigation of molecular mechanisms contributing to β-cell dysfunction and the development of diabetes, as well as the identification and verification of circulating biomarkers of β-cell dysfunction.
I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Levings is a Professor in the Department of Surgery and School of Biomedical Engineering at the University of British Columbia. Her lab studies the biology and clinical application of a special kind of white blood cell, known as a T regulatory cell, that can be used as cellular therapy to stop harmful immune responses. She is internationally recognized in the field of human immunology and currently chairs the Federation of Clinical Immunology Societies Centers' of Excellence and is a member of the NIH-funded Immune Tolerance Network Steering Committee.
I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Treena Wasonti:io Delormier is Kanien’kehá:ka (Mohawk). She is an Associate Professor in the School of Human Nutrition at McGill University, and Associate Director of the Centre for Indigenous Peoples Nutrition and Environment. She is the Scientific Director of the Kahnawake Schools Diabetes Prevention Project (KSDPP), a 24-year community-university partnership and health promotion program in her home community of Kahnawake, near Montreal, Quebec. Dr. Delormier’s research interests include Indigenous research methodologies, qualitative methodologies, Indigenous Peoples’ food systems and the prevention of diabetes and obesity prevention through community mobilization strategies.
I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Diffey is a member of the Peepeekisis Cree Nation in the Treaty 4 region and Indigenous Scholar in Community Health Sciences and Ongomiizwin Indigenous Institute of Health and Healing. She co-led the development and implementation of the Indigenous Health curriculum in undergraduate medical education at the Max Rady College of Medicine and served as a co-editor of the national undergraduate medicine curricular framework for Indigenous health that was developed by the Indigenous Physicians Association of Canada and the Association of Faculties of Medicine of Canada.
Linda is a PhD candidate in the Applied Health Sciences Program at the University of Manitoba. Her dissertation work focuses on the experiences of physician instructors during the implementation of anti-colonial, anti-racist pedagogy in medical education. Other areas of interest include examining systemic colonial oppression within health-related institutions and the application of Indigenous resurgence as a theoretical foundation within Indigenous research methodology.
She has been actively engaged in the mentorship and support of Indigenous students in health research and education for over ten years, and is co-Principal Investigator of the Prairie Indigenous Knowledge Exchange Network (PIKE-Net), part of the CIHR Indigenous Mentorship Network program. In 2018, she was awarded an Indigenous Award of Excellence in the Community Builder category in recognition of her work that seeks to create a safe and supportive work and learning environment for Indigenous students, faculty and staff at the University of Manitoba.
I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Butalia is a Clinician Scientist in the Departments of Medicine and Community Health Sciences at the University of Calgary. Her research interests are in innovative tools and strategies to improve diabetes and other cardiovascular risk factors in the community. Her program of work importantly engages and is informed by people (i.e. patient partners), health-care providers and decision makers. Her research program is supported by CIHR, Diabetes Canada, the Heart and Stroke Foundation of Canada and Alberta Health Services. Dr. Butalia is also a co-author of several national guidelines in diabetes and hypertension and has contributed to several textbooks. She also teaches at the University of Calgary’s medical school, supervises trainees, and was awarded a Gold Star Resident Teaching Award for her contributions. Finally, she has recently become the Scientific Director of the Diabetes, Obesity and Nutrition Strategic Clinical Network for the province of Alberta.
I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Funded, peer-reviewed grants from not-for profit organizations: Diabetes Canada, Heart and Stroke Foundation of Canada, Alberta Health Services
Katie Pundyk is a Pediatric Endocrinologist at the Winnipeg Children's Hospital, and an Assistant Professor at the University of Manitoba. She completed her Pediatrics residency at the University of Manitoba, and her clinical Pediatric Endocrinology fellowship at the University of Ottawa. She completed an additional year of research training at the University of Manitoba focusing on transition of care in youth with type 2 diabetes, with funding from the Children's Hospital Research Institute of Manitoba and Manitoba Medical Service Foundation.
I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Lim is an Assistant Professor in the Department of Medicine at the University of Montréal and a Principal Scientist at the University of Montreal Hospital Research Centre (CRCHUM). Currently, he holds the Canada Research Chair in Adipocyte Development. His research is focused on understanding the metabolic functions of the scaffold protein in fat cells and pancreatic beta-cells, and his lab is currently supported by CIHR and NSERC.
I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose
During my graduate studies (MSc/PhD, Université Laval, 2002-2007), I developed an expertise in physiology and endocrinology, focusing my attention on adipose tissue metabolism in response to PPARg agonists. In order to improve my capacity to further characterize and understand the molecular mechanisms controlling cellular metabolism, I joined the laboratory of David M. Sabatini (Massachusetts Institute of Technology (MIT)), a world expert in cell signaling primarily known for its work with the kinase mTOR. Over the years that followed (2007-2011), I have been involved in many projects aimed at characterizing the role of mTOR in health, diseases and aging. Over these years, I have published several original articles and reviews on the mTOR pathway. During my postdoctoral training, I learned and mastered several state-of-the-art techniques in molecular biology. I also got the chance to learn how to generate transgenic mouse models. This unique expertise in physiology and molecular biology has greatly helped the establishment of my own laboratory in 2011 (Université Laval). Today, I lead a group of young scientists whose primary objective is to improve the understanding of the molecular mechanisms controlling metabolism in response to environmental challenges. We have a special interest in identifying new biological processes controlling the early development of white adipocytes.
I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Little is an Associate Professor in the School of Health and Exercise Sciences at the University of British Columbia in Kelowna, BC, Canada. He is a Canadian Institutes of Health Research (CIHR) New Investigator and Michael Smith Foundation for Health Research (MSFHR) Scholar whose research focuses on optimizing diet and exercise interventions for the prevention and treatment of type 2 diabetes. He has published over 115 peer-reviewed journal articles in the areas of exercise metabolism, nutrition, type 2 diabetes, obesity and immunology. Ongoing nutrition studies in his lab are exploring how low-carbohydrate diets, nutritional ketosis, and exercise impact glucose control, cardiovascular risk and inflammation.
Dr. Panda is a Professor at the Salk Institute, La Jolla, California. His research focuses on circadian coordination of behavior, physiology and metabolism. His discovery of how a blue light sensor in the eyes affects sleep-wake cycle, depression and alertness is leading a new revolution in managing light to improve health. Recently, Dr. Panda discovered that maintaining a daily feeding-fasting cycle – popularly known as Time-restricted eating (TRE) – can prevent and reverse many chronic diseases and increase lifespan. His lab uses Drosophila, rodents and primates for a mechanistic understanding of the role of circadian rhythm in health. His lab has developed a smartphone app “myCircadianClock,” to facilitate translation of his research to human patients.
I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Dr. Peter Lin is the Director of Primary Care Initiatives at the Canadian Heart Research Centre. He has a busy family practice in Toronto, Canada. He is also a contributing author to the Canadian Diabetes Guidelines 2013 and 2018 on the vascular protection section. He is also Associate Editor for the Elsevier WebPortal - PracticeUpdate Primary Care. Dr. Lin is also the health columnist for CBC and has been actively tracking the COVID-19 Pandemic since the beginning.
Dr. Ilana Halperin is a staff endocrinologist at Sunnybrook and assistant professor of Medicine at The University of Ontario. She is the Quality and Innovation lead for the Division of Endocrinology and Medical Director of the Diabetes in Pregnancy Program at Sunnybrook. She was an early adopter of virtual care and has an expertise in leveraging technology to optimize care.
Speakers Fees: Sanofi, Novonordisk, Boehringer Ingelheim, Dexcom Canada, Abbott Diabetes Care
Advisory Boards: Sanofi, Novonordisk, Dexcom Canada, Abbott Diabetes Care
Site for clinical trials: Novonordisk
Dr. Nagarajah is a professor for Nuclear Medicine currently appointed in September 2016 as Assistant Professor in Radboud University Medical Center in Nijmegen, The Netherlands. He started his medical training in July 2004 in the department of Nuclear Medicine in Wuppertal, Germany and moved to University Hospital in Essen, Germany to accomplish his training. Here, he was appointed as an attending physician and the head of the PET centre from November 2011 on. From July 2013, he was appointed as a Visiting Investigator in Memorial Sloan Kettering Cancer Center, New York, USA, where he became a Visiting Professor in July 2015. Here, he worked with Professors Wolfgang Weber and James Fagin focusing on re-differentiation approaches in radio-iodine refractory thyroid cancer. He is a PI in many ongoing prospective investigator-initiated clinical studies for advanced thyroid cancer and prostate cancer using different radio-ligands for theranostics.
I have a relationship with a for-profit and/or a not-for-profit organization to disclose
Teaching: Genzyme and Sanofi
Clinical Studies: ABX, Ger
"Dr. Hattersley is the Professor of Molecular Medicine at the University of Exeter, UK and a practicing consultant Diabetologist at the Royal Devon and Exeter hospital. He trained in Medicine at the Universities of Cambridge and Oxford. His postgraduate education was in London, Oxford and Birmingham. Since he moved to Exeter in 1995, he has published over 600 papers, given more than 300 national and international lectures and received many national and international awards for his research, including being appointed as a Fellow of The Royal Society in 2010 and being awarded a CBE in 2017.
Dr. Hattersley is a Clinician Scientist who has made outstanding scientific discoveries in diabetes that have transformed our understanding, diagnosis and treatment of genetic forms of diabetes.
In 1995, he and Sian Ellard established a genetic laboratory in Exeter that is now world leading for monogenic diabetes diagnosis and research; receiving over 20,000 samples from 104 countries. They have described alone, or with others, 24 new genetic causes of diabetes; over half of all genetic subtypes.
Dr. Hattersley has led the studies which have carefully characterized the diabetes and other clinical features of these patients. These findings have been central in improving diagnosis, management and treatment for patients with monogenic diabetes throughout the world. Dr. Hattersley’s major advance has been to take beta-cell science into treatment of patients. After proving mutations in the beta-cell potassium channel were the most common cause of neonatal diabetes, he went on to show that these patients could replace their insulin injections with sulphonylurea tablets and improve blood glucose control. He ensured patients benefitted by offering free genetic testing for every patient with diabetes in the world diagnosed before 6 months.
He continues to identify new and important genes for beta-cell development, function and destruction by studying neonatal diabetes patients. Gene discovery in patients with a complete failure of pancreas development has shown that early human beta-cell development differs markedly from mice; this is critical information for creating human beta-cell replacement therapy from stem cells. For Dr. Hattersley, the patient is always the focus of his science.
Clinical Assistant Professor, University of British Columbia, BC
Grants/Research Support: AstraZeneca, CHRC, Novo Nordisk, Sanofi
Speakers Bureau/Honoraria: Abbott, AstraZeneca, Boehringer Ingelheim, CCRN, CPD network, Dexcom, Janssen, Lilly, MD Briefcase, Medtronic, Merck, Novo Nordisk, Sanofi
Consulting Fees: Abbott, AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk
Clinical Associate Professor, Department of Family Medicine, Cumming School of Medicine, University of Calgary, Alberta
Advisory Boards: Abbott, Aralez, AstraZeneca, Janssen, Novo Nordisk
Speaker: AstraZeneca, GSK, Lilly, Merck, Novo Nordisk,
Education: Alberta Innovates, Novo Nordisk, University of Calgary Adjudicator: Diabetes Canada
Representative Forum Delegate: Alberta Medical Association
Collaborative Community Pharmacist, Consultant, Rothesay, NB
Grants/Research Support: Boehringer Ingelheim, MontMed Canada, New Brunswick Health Research Foundation Speakers Bureau/Honoraria: Abbott Diabetes Care Canada, Allied Pharmacists Inc., AstraZeneca Canada, Bausch Health (Valeant [Bio-Vail] Pharmaceuticals), Bayer Healthcare, Becton Dickinson Canada, Boehringer-Ingelheim Canada, Canadian Pharmacists Association, Diabetes Canada, HLS Therapeutics, Janssen Canada, Lilly Canada, MDBriefcase, MontMed Canada, Novo Nordisk, Roche Diagnostics, RxBriefcase, Sanofi Canada
Consulting Fees: Abbott Diabetes Care, AstraZeneca Canada, Becton Dickinson Canada, Boehringer-Ingelheim Canada, Canadian Pharmacists Association, HLS Therapeutics, Janssen Pharmaceuticals, Lilly Canada, Merck Canada, MontMed Canada, New Brunswick Government - Department of Health - (Diabetes Task Force), Novo Nordisk, Sanofi Canada
Clinical Nurse Specialist and Nurse Consultant, Toronto, ON
Speakers Bureau/Honoraria: BD, Diabetes Canada, Lilly, Novo Nordisk
Facilitation: Diabetes Care Community
Diabetes Action Canada Trainee Day
Diabetes Canada and Diabetes Action Canada are pleased to announce the Virtual Trainee Day: Shifting the Paradigm in Patient-Oriented Research: Are We There Yet? It will take place on Tuesday, October 27th, 2020 from 11:00 a.m. to 4:00 p.m. prior to the 2020 Diabetes Canada/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings.
This is an excellent opportunity for trainees to learn about Patient-Oriented Research (POR) through patient partner stories, hone your grant writing skills, improve team building and learn about POR Decision tools
CSEM Residents’ Day Review
The Canadian Society of Endocrinology and Metabolism (CSEM) is excited to announce that the 2020 Residents' Day Review Course will be offered virtually on Tuesday, October 27, 2020 from 11:00 a.m. to 4:00 p.m., prior to the 2020 Diabetes Canada/Canadian Society of Endocrinology and Metabolism Professional Conference. Residents’ Day is FREE for CSEM Resident Members - Join CSEM. The day’s agenda will be posted on the CSEM website once confirmed.
Resident clinical vignettes and research project abstracts can be submitted here before September 7, 2020.
Residents’ Day consists of workshops and lectures on endocrinology topics led by experts in the field. It is specially designed to prepare you for the upcoming Royal College of Physicians and Surgeons of Canada certification exam in endocrinology.
The full conference registration fee includes access to all sessions, exhibits, posters, and sponsored events.
Registration Category | Until Aug 12, 2020 | Aug 13-Oct 21 | Oct 22-30 |
---|---|---|---|
DIABETES CANADA / CSEM PROFESSIONAL MEMBER | |||
Member Full Conference Pass | $100 | $120 | $145 |
One Day Member Conference Pass | $75 | $100 | N/A |
NON-MEMBER | |||
Non-Member Full Conference Pass | $200 | $250 | $300 |
One Day Non-Member Conference Pass | $175 | $225 | N/A |
MEMBER OPPORTUNITIES | |||
Diabetes Canada Professional Membership* | $75 | $105 | $105 |
Diabetes Canada Professional Membership (trainee, student) | $0 | $0 | $0 |
All post-secondary students (e.g. Bachelors, Masters, PhD, post- doctoral or M.D.) enrolled at a college or university in a diabetes/health-care related field are eligible to become student members.
Student members enjoy the same benefits as regular members free of charge for up to two years.
Complete the application form and email it along with your proof of enrollment to professional.membership@diabetes.ca. All applicants must provide proof of full-time status that confirms the start and end dates of their program.
The vFairs platform includes the following accessibility features: